-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BTHCNNh2iiR5HEuaXyFpDQQw6Oo54d/kWAwDt1vxffpH8Dqw+iahGlR+LorcMqfj gJZXZ2LvZk3Yg+TgWsv1OQ== 0000912057-02-006858.txt : 20020414 0000912057-02-006858.hdr.sgml : 20020414 ACCESSION NUMBER: 0000912057-02-006858 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20020219 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF INVESTMENTS, L.L.C. GROUP MEMBERS: BVF PARTNERS, L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-59397 FILM NUMBER: 02553511 BUSINESS ADDRESS: STREET 1: 6166 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584537200 MAIL ADDRESS: STREET 1: 6166 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 415-288-23 MAIL ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 SC 13G 1 a2071355zsc13g.htm SC 13G

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No.[  ])1


Arena Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

 

 

040047 10 2

 

 
   
(CUSIP Number)
   

February 7, 2002

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

        / /      Rule 13d-1(b)

        /x/      Rule 13d-1(c)

        / /      Rule 13d-1(d)


1
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 040047 10 2   13G   Page  2  of  9  Pages

       


1.   NAME OF REPORTING PERSON.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY).

 

 

Biotechnology Value Fund, L.P.

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) /x/
    (b) / /

3.   SEC USE ONLY
     

4.   CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware

NUMBER OF   5.   SOLE VOTING POWER    -0-
SHARES  
BENEFICIALLY   6.   SHARED VOTING POWER    521,600
OWNED BY EACH  
REPORTING   7.   SOLE DISPOSITIVE POWER    -0-
PERSON WITH  
    8.   SHARED DISPOSITIVE POWER    521,600

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
521,600

10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    / /

11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    1.9%

12.   TYPE OF REPORTING PERSON*
    PN

SEE INSTRUCTIONS BEFORE FILLING OUT!


CUSIP No. 040047 10 2   13G   Page  3  of  9  Pages

       


1.   NAME OF REPORTING PERSON.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY).

 

 

Biotechnology Value Fund II, L.P.

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) /x/
    (b) / /

3.   SEC USE ONLY
     

4.   CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware

NUMBER OF   5.   SOLE VOTING POWER    -0-
SHARES  
BENEFICIALLY   6.   SHARED VOTING POWER    328,300
OWNED BY EACH  
REPORTING   7.   SOLE DISPOSITIVE POWER    -0-
PERSON WITH  
    8.   SHARED DISPOSITIVE POWER    328,300

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
328,300

10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    / /

11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    1.2%

12.   TYPE OF REPORTING PERSON*
    PN

SEE INSTRUCTIONS BEFORE FILLING OUT!


CUSIP No. 040047 10 2   13G   Page  4  of  9  Pages

       


1.   NAME OF REPORTING PERSON.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY).

 

 

BVF INVESTMENTS, L.L.C.

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) /x/
    (b) / /

3.   SEC USE ONLY
     

4.   CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware

NUMBER OF   5.   SOLE VOTING POWER    -0-
SHARES  
BENEFICIALLY   6.   SHARED VOTING POWER    754,500
OWNED BY EACH  
REPORTING   7.   SOLE DISPOSITIVE POWER    -0-
PERSON WITH  
    8.   SHARED DISPOSITIVE POWER    754,500

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
754,500

10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    / /

11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    2.7%

12.   TYPE OF REPORTING PERSON*
    OO

SEE INSTRUCTIONS BEFORE FILLING OUT!


CUSIP No. 040047 10 2   13G   Page  5  of  9  Pages

       


1.   NAME OF REPORTING PERSON.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY).

 

 

BVF PARTNERS, L.P.

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) /x/
    (b) / /

3.   SEC USE ONLY
     

4.   CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware

NUMBER OF   5.   SOLE VOTING POWER    -0-
SHARES  
BENEFICIALLY   6.   SHARED VOTING POWER    1,677,600
OWNED BY EACH  
REPORTING   7.   SOLE DISPOSITIVE POWER    -0-
PERSON WITH  
    8.   SHARED DISPOSITIVE POWER    1,677,600

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,677,600

10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    / /

11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    6.1%

12.   TYPE OF REPORTING PERSON*
    PN

SEE INSTRUCTIONS BEFORE FILLING OUT!


CUSIP No. 040047 10 2   13G   Page  6  of  9  Pages

       


1.   NAME OF REPORTING PERSON.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY).

 

 

BVF INC.

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) /x/
    (b) / /

3.   SEC USE ONLY
     

4.   CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware

NUMBER OF   5.   SOLE VOTING POWER    -0-
SHARES  
BENEFICIALLY   6.   SHARED VOTING POWER    1,677,600
OWNED BY EACH  
REPORTING   7.   SOLE DISPOSITIVE POWER    -0-
PERSON WITH  
    8.   SHARED DISPOSITIVE POWER    1,677,600

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,677,600

10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    / /

11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    6.1%

12.   TYPE OF REPORTING PERSON*
    IA, CO

SEE INSTRUCTIONS BEFORE FILLING OUT!


CUSIP No. 040047 10 2   13G   Page  7  of  9  Pages

ITEM 1(a).

 

Name of Issuer:

 

 

Arena Pharmaceuticals, Inc. ("Arena")

ITEM 1(b).

 

Address of Issuer's Principal Executive Offices:

 

 

6166 Nancy Ridge Drive
San Diego, California 92121

ITEM 2(a).

 

Name of Persons Filing:

 

 

This Schedule 13G is being filed on behalf of the following persons* (the "Reporting Persons"):

 

 

(i)

Biotechnology Value Fund, L.P. ("BVF")
    (ii) Biotechnology Value Fund II, L.P. ("BVF2")
    (iii) BVF Investments, L.L.C. ("Investments")
    (iv) BVF Partners L.P. ("Partners")
    (v) BVF Inc. ("BVF Inc.")

 

 

*

Attached as Exhibit 1 is a copy of an agreement among the Reporting Persons filing (as specified hereinabove) that this Schedule 13G is being filed on behalf of each of them.

ITEM 2(b).

 

Address of Principal Business Office:

 

 

The principal business office of the Reporting Persons comprising the group filing this Schedule 13G is located at 227 West Monroe Street, Suite 4800, Chicago, Illinois, 60606.

ITEM 2(c).

 

Citizenship:

 

 

BVF:

a Delaware limited partnership
    BVF2: a Delaware limited partnership
    Investments: a Delaware limited liability company
    Partners: a Delaware limited partnership
    BVF Inc.: a Delaware corporation

ITEM 2(d).

 

Title of Class of Securities:

 

 

Common Stock

ITEM 2(e).

 

CUSIP Number:

 

 

040047 10 2

CUSIP No. 040047 10 2   13G   Page  8  of  9  Pages

ITEM 3.

 

IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS: One of the following

 

 

Not applicable as this Schedule 13G is filed pursuant to Rule 13d 1(c).

ITEM 4.

 

OWNERSHIP:

 

 

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 6) on this Schedule 13G is hereby incorporated by reference.

ITEM 5.

 

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

 

 

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following. / /

ITEM 6.

 

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

 

 

BVF shares voting and dispositive power over the shares of the common stock it beneficially owns with Partners. BVF2 also shares voting and dispositive power over the shares of the common stock it beneficially owns with Partners. Investments also shares voting and dispositive power over the shares of the common stock it beneficially owns with Partners. Partners and BVF Inc. share voting and dispositive power over the shares of the common stock they beneficially own with, in addition to BVF, BVF2 and Investments, certain managed accounts on whose behalf Partners, as investment manager, purchased such shares. None of the managed accounts individually owns more than 5% of the common stock of Arena.

ITEM 7.

 

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

 

 

Not applicable.

ITEM 8.

 

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

 

 

Not applicable.

ITEM 9.

 

NOTICE OF DISSOLUTION OF GROUP.
    Not applicable.

CUSIP No. 040047 10 2   13G   Page  9  of  9  Pages

ITEM 10.    CERTIFICATION.

        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

        After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated February 19, 2002.

    BIOTECHNOLOGY VALUE FUND, L.P.  

 

 

By:

BVF Partners L.P., its general partner

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

By:

 

 
          /s/  MARK N. LAMPERT      
Mark N. Lampert
President
 

 

 

 

 

 

 

 
    BIOTECHNOLOGY VALUE FUND II, L.P.  

 

 

By:

BVF Partners L.P., its general partner

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

By:

 

 
          /s/  MARK N. LAMPERT      
Mark N. Lampert
President
 

 

 

 

 

 

 

 
    BVF INVESTMENTS, L.L.C.  

 

 

By:

BVF Partners L.P., its general partner

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

By:

 

 
          /s/  MARK N. LAMPERT      
Mark N. Lampert
President
 

 

 

 

 

 

 

 
    BVF PARTNERS L.P.  

 

 

By:

BVF Inc., its general partner

 

 

 

 

By:

 

 

 

 

 

 

 

/s/  
MARK N. LAMPERT      
Mark N. Lampert
President

 

 

 

 

 

 

 

 
    BVF INC.  

 

 

By:

 

 

 

 
      /s/  MARK N. LAMPERT      
Mark N. Lampert
President
 

 

 

 

 

 

 

 


EX-1 3 a2071355zex-1.htm EXHIBIT 1
QuickLinks -- Click here to rapidly navigate through this document

EXHIBIT 1

AGREEMENT REGARDING JOINT FILING

        The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, BVF Investments, L.L.C., a Delaware limited liability company, BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the information required by Schedule 13G, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.

Dated February 19, 2002.

    BIOTECHNOLOGY VALUE FUND, L.P.  

 

 

By:

BVF Partners L.P., its general partner

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

By:

 

 
          /s/  MARK N. LAMPERT      
Mark N. Lampert
President
 

 

 

 

 

 

 

 
    BIOTECHNOLOGY VALUE FUND II, L.P.  

 

 

By:

BVF Partners L.P., its general partner

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

By:

 

 
          /s/  MARK N. LAMPERT      
Mark N. Lampert
President
 

 

 

 

 

 

 

 
    BVF INVESTMENTS, L.L.C.  

 

 

By:

BVF Partners L.P., its general partner

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

By:

 

 
          /s/  MARK N. LAMPERT      
Mark N. Lampert
President
 

 

 

 

 

 

 

 
    BVF PARTNERS L.P.  

 

 

By:

BVF Inc., its general partner

 

 

 

 

By:

 

 

 

 

 

 

 

/s/  
MARK N. LAMPERT      
Mark N. Lampert
President

 

 

 

 

 

 

 

 
    BVF INC.  

 

 

By:

 

 

 

 
      /s/  MARK N. LAMPERT      
Mark N. Lampert
President
 

 

 

 

 

 

 

 



QuickLinks

AGREEMENT REGARDING JOINT FILING
-----END PRIVACY-ENHANCED MESSAGE-----